Baltimore Washington Financial Advisors Inc. reduced its stake in shares of Celgene Corp. (NASDAQ:CELG) by 5.6% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 28,094 shares of the biopharmaceutical company’s stock after selling 1,665 shares during the period. Baltimore Washington Financial Advisors Inc.’s holdings in Celgene Corp. were worth $2,937,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of CELG. Vanguard Group Inc. raised its stake in shares of Celgene Corp. by 0.8% in the second quarter. Vanguard Group Inc. now owns 47,833,717 shares of the biopharmaceutical company’s stock worth $4,717,840,000 after buying an additional 395,600 shares in the last quarter. BlackRock Institutional Trust Company N.A. increased its position in shares of Celgene Corp. by 0.6% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 20,241,642 shares of the biopharmaceutical company’s stock worth $1,996,433,000 after buying an additional 117,543 shares during the last quarter. BlackRock Fund Advisors increased its position in shares of Celgene Corp. by 0.3% in the second quarter. BlackRock Fund Advisors now owns 15,066,831 shares of the biopharmaceutical company’s stock worth $1,486,042,000 after buying an additional 48,168 shares during the last quarter. Carmignac Gestion increased its position in shares of Celgene Corp. by 28.1% in the second quarter. Carmignac Gestion now owns 9,708,359 shares of the biopharmaceutical company’s stock worth $957,535,000 after buying an additional 2,127,659 shares during the last quarter. Finally, TIAA CREF Investment Management LLC increased its position in shares of Celgene Corp. by 0.3% in the second quarter. TIAA CREF Investment Management LLC now owns 8,306,276 shares of the biopharmaceutical company’s stock worth $819,248,000 after buying an additional 22,264 shares during the last quarter. 76.43% of the stock is currently owned by institutional investors.

Institutional Ownership by Quarter for Celgene Corp. (NASDAQ:CELG)

Celgene Corp. (NASDAQ:CELG) traded up 1.52% during midday trading on Tuesday, hitting $122.13. The company had a trading volume of 4,450,492 shares. The stock has a market cap of $94.68 billion, a price-to-earnings ratio of 46.38 and a beta of 1.71. Celgene Corp. has a 12-month low of $93.05 and a 12-month high of $127.00. The company’s 50 day moving average is $108.88 and its 200 day moving average is $106.73.

Celgene Corp. (NASDAQ:CELG) last announced its earnings results on Thursday, October 27th. The biopharmaceutical company reported $1.58 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.48 by $0.10. Celgene Corp. had a return on equity of 70.48% and a net margin of 19.71%. The firm had revenue of $2.98 billion for the quarter, compared to analysts’ expectations of $2.84 billion. During the same quarter in the previous year, the company earned $1.23 earnings per share. The firm’s quarterly revenue was up 27.8% compared to the same quarter last year. On average, equities analysts anticipate that Celgene Corp. will post $5.92 EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This piece of content was first published by The Cerbat Gem and is the propert of of The Cerbat Gem. If you are viewing this piece of content on another website, it was copied illegally and reposted in violation of U.S. and international copyright legislation. The correct version of this piece of content can be viewed at https://www.thecerbatgem.com/2016/11/29/celgene-corp-celg-shares-sold-by-baltimore-washington-financial-advisors-inc.html.

A number of equities analysts recently commented on the company. Oppenheimer Holdings Inc. assumed coverage on Celgene Corp. in a research report on Tuesday. They set an “outperform” rating and a $141.00 price objective on the stock. Vetr upgraded Celgene Corp. from a “hold” rating to a “buy” rating and set a $128.85 price objective on the stock in a research report on Tuesday. Cann assumed coverage on Celgene Corp. in a research report on Monday. They set an “outperform” rating and a $141.00 price objective on the stock. Standpoint Research downgraded Celgene Corp. from a “buy” rating to a “hold” rating in a research report on Wednesday, November 9th. Finally, Mizuho started coverage on Celgene Corp. in a research report on Monday, November 7th. They set a “buy” rating and a $130.00 price objective on the stock. Four research analysts have rated the stock with a hold rating and twenty-seven have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of $136.62.

In related news, Director Gilla Kaplan sold 9,710 shares of the business’s stock in a transaction that occurred on Thursday, September 15th. The stock was sold at an average price of $106.44, for a total transaction of $1,033,532.40. Following the sale, the director now owns 72,142 shares of the company’s stock, valued at $7,678,794.48. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, major shareholder Corp /De/ Celgene bought 800,150 shares of the company’s stock in a transaction that occurred on Monday, October 24th. The shares were purchased at an average cost of $14.00 per share, for a total transaction of $11,202,100.00. The disclosure for this purchase can be found here. Corporate insiders own 0.97% of the company’s stock.

About Celgene Corp.

Celgene Corporation (Celgene) is a biopharmaceutical company. The Company together with its subsidiaries is engaged primarily in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

5 Day Chart for NASDAQ:CELG

Receive News & Stock Ratings for Celgene Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corp. and related stocks with our FREE daily email newsletter.